FTC report shows $7.3 billion in drug price inflation by leading pharmacy benefit managers
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Straight Arrow News on MSN7h
'Big 3' pharmacy benefit managers marked up drugs by $7.3B: FTC
The three biggest pharmacy benefit managers marked up "lifesaving" medications to generate $7.3 billion in five years, according to the FTC.
Report: 'Pharmacy Benefit Managers' profited billions by raising prices of 'specialty drugs'
The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...
Honolulu Star-Advertiser10h
FTC: Pharmacy benefit managers inflated drug prices by $7.3B
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
BioSpace15h
Pharmacy Benefits Managers Netted Extra $7.3B by Inflating Drug Prices: FTC
A report published Tuesday shows hundreds and thousands of percent markups on HIV, hypertension and cancer drugs for Medicare ...
ConsumerAffairs17h
Another FTC report is highly critical of pharmacy benefit managers
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
KITV10h
Pharmacy benefit managers marked up drug prices by $7.3B, new reports finds
A new FTC report blames Pharmacy Benefit Managers for marking up specialty drug prices, profiting $7.3 billion from cancer and HIV treatments between 2017-2022.
UnitedHealth, employer of slain exec Brian Thompson, found to have overcharged some cancer patients for drugs by over 1,000%
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
Lawmaker may file bill to regulate PBMs: “They’re managing the dollar bill”
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
Pharma middlemen marked up $7.3B
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
pharmaphorum17h
FTC doubles down on PBM criticism in new report
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...